Corbus Pharmaceuticals Holdings, Inc. (CRBP)
AI stock analysis · as of May 26, 2026
Loading microstructure…
Corbus Pharmaceuticals (CRBP) is a clinical-stage biotech with two assets: CRB-701, a Nectin-4 ADC with early Phase 1/2 ORRs of 47.6% (HNSCC) and 55.6% (mUC) and a cleaner safety profile than approved PADCEV, and CRB-913, an oral peripherally-restricted CB1 inverse agonist for obesity showing 2.9% placebo-adjusted weight loss at 14 days with no GI toxicity. The core question is whether $28M of cash plus ATM/debt capacity can fund ~$70M annual R&D burn long enough to deliver de-risking catalysts (Q1 2026 FDA meeting, CANYON-1 readout summer 2026) before dilution or a clinical setback impairs the equity—particularly after a ~26% single-day post-ASCO selloff signaled buy-side disappointment.
valuationOptically cheap at 1.1x P/B and ~$146M market cap with two clinical assets, but valuation is binary—negative EV/EBITDA and -$5.74 EPS make multiples meaningless; this is a probability-weighted clinical option, not a multiples story.
This analysis is from May 26, 2026. Want the latest on CRBP, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · CRB-701 ORRs of 47.6% in HNSCC and 55.6% in mUC at 3.6 mg/kg with only 8.4% peripheral neuropathy and 1.8% Grade 3+ skin events compare favorably to PADCEV's known toxicity profile, supporting a differentiated Nectin-4 ADC opportunity
- · Q1 2026 FDA meeting to align on registrational design for HNSCC/cervical cancer is a major de-risking event that could re-rate the stock
- · CRB-913 is mechanistically differentiated from GLP-1s (oral, no GI side effects, potentially preserves muscle mass), addressing a real unmet need in GLP-1 non-responders/intolerants; Phase 1b CANYON-1 reads out summer 2026
- · CSPC's separately funded Phase 3 of CRB-701 in cervical cancer in China provides free optionality and additional data sets
- · Stock trades at ~$146M market cap and 1.1x price-to-book vs. analyst consensus target of $38.80 (10 analysts, strong buy), implying ~390% upside if street is right
- · 71.9% institutional ownership and recent high-profile executive hires suggest sophisticated capital believes in the platform
Bear case
- · Market reaction to ASCO CRB-701 data was a ~26% single-day decline—buy-side voted that the data underwhelmed regardless of analyst defenses
- · R&D expense surged 118% YoY to $70.1M against $28.5M cash and zero revenue; FCF of -$64.5M implies <6 months runway without ATM dilution at a depressed share price
- · CB1 antagonist class carries serious baggage—rimonabant was withdrawn in EU for neuropsychiatric events, and CRB-913 already showed mild anxiety/irritability signals at 150 mg, creating a regulatory ceiling
- · Nectin-4 competitive field is crowded with approved PADCEV (Pfizer/Astellas), Bicycle Therapeutics, and Mabwell; differentiation must be confirmed in randomized trials
- · CRB-913 IP under Jenrin license expires November 2028 in the U.S.; owned patent extensions to 2043-2046 are not yet granted, creating a potential generic cliff before peak sales
- · Only 17.7M shares outstanding combined with cash-burn-dependent ATM usage means equity dilution risk is severe at sub-$10 levels
- · K2HV debt covenants could trigger liquidity squeeze if clinical milestones slip
Catalysts
- · Q1 2026 FDA Type B meeting on CRB-701 registrational design for HNSCC and cervical cancer
- · CRB-701 + pembrolizumab combination arm initial data (initiated June 2025)
- · CANYON-1 Phase 1b CRB-913 readout in obesity, summer 2026 (240 subjects, 12 weeks)
- · Next earnings 2026-08-11 with cash runway update and likely financing commentary
- · Short interest at 9.2% of float with 5.3 days to cover provides modest squeeze potential on positive data
- · CSPC China Phase 3 cervical cancer trial progression updates
Key risks
- · Dilutive equity financing via Jefferies ATM at depressed prices given <6 months cash runway at current burn
- · CRB-913 neuropsychiatric signals worsen at higher doses in Phase 1b, killing the obesity asset
- · FDA requires a larger/longer randomized registrational trial for CRB-701, pushing approval and revenue out years
- · Competitive Nectin-4 readouts from Bicycle/Mabwell or PADCEV label expansions erode CRB-701's commercial opportunity
- · K2HV loan covenant breach forces restructuring or unfavorable refinancing
What to watch
- · Next earnings 2026-08-11—cash position, burn trajectory, and ATM usage disclosure
- · Any 8-K announcing FDA Q1 2026 meeting outcome on CRB-701 registrational design
- · $6.72 52-week low as key technical support; break risks capitulation funding round
- · CANYON-1 enrollment/interim safety updates ahead of summer 2026 topline
- · Short interest trend (currently 9.2%) and institutional 13F changes given 71.9% institutional ownership
- · Competitive Nectin-4 ADC and CB1 obesity readouts from Bicycle, Mabwell, Skye Bioscience
Key metrics
Price target rationale
Base $12 reflects modest re-rating on FDA alignment for CRB-701 and clean interim CANYON-1 safety, partially offset by ~30-40% dilution to extend runway. Bull $28 assumes positive FDA registrational path plus clean CANYON-1 efficacy, supporting risk-adjusted peak sales modeling on both assets. Bear $3 reflects another disappointing readout or dilutive raise at distressed prices and possible CB1 program suspension.
On Wall Street's view (mixed): The $38.80 consensus target (390% upside) reflects success-case sum-of-parts on both assets but appears to under-weight the post-ASCO data reception, dilution math, and CB1-class regulatory overhang. A target in the high teens to low $20s better balances clinical optionality with funding risk.
Latest filing (10-K)
Corbus is a cash-burning clinical-stage biotech with two genuinely differentiated assets—a cleaner Nectin-4 ADC showing 48-56% ORRs and an oral CB1 obesity pill with early weight loss and no GI toxicity—but it must survive on a ~$68M market cap while spending $70M/year in R&D before any revenue exists.
Corbus Pharmaceuticals (CRBP) is a clinical-stage biopharmaceutical company with no commercial revenue, focused on oncology and obesity. It generates no product sales and funds operations through equity offerings and debt. Its two lead programs are CRB-701, a next-generation Nectin-4-targeting antibody-drug conjugate (ADC) licensed from CSPC for Western markets, and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity.
What the news says · bearish
The dominant storyline is a sharp ~26% single-day sell-off following the release of updated Phase 1/2 CRB-701 trial data at ASCO, suggesting the clinical readout disappointed investors despite some headlines framing the data as 'promising.' The market reaction is the clearest signal: even with HC Wainwright maintaining a $40 price target and at least one analyst calling the weakness 'mispriced,' the stock cratered, indicating the data fell short of buy-side expectations. Some coverage notes tumor shrinkage in HPV-linked cancers, which is a positive signal, but early-stage oncology data is notoriously difficult to interpret and the selloff implies the efficacy or safety profile underwhelmed. Pre-ASCO insider equity grants and a high-profile hire (former Evercore MD) had set up bullish expectations that the data release failed to meet. Coverage is reasonably active but concentrated on a single catalyst day, so the bearish read is driven almost entirely by the price action and trial data reaction.
This analysis is from May 26, 2026. Markets move. Get the current read on CRBP and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.